Myrup B, Jensen T, Gram J, Kluft C, Jespersen J, Deckert T
Steno Diabetes Center, Gentofte, The Netherlands.
Diabetes Care. 1997 Oct;20(10):1615-9. doi: 10.2337/diacare.20.10.1615.
The high risk for cardiovascular disease in IDDM patients with nephropathy may be mediated by abnormal function of the vascular wall. We investigated whether heparin was able to modulate markers of vascular wall and hemostatic function in patients with incipient nephropathy.
Thirty-five IDDM patients with incipient nephropathy were randomized to treatment with placebo, unfractioned heparin, or low molecular weight heparin in a double-blind trial. The treatment was given as 1 h of conventional intravenous high-dose treatment and in a conventional subcutaneous low-dose regime for 3 months. Transcapillary escape rate of albumin and plasma levels of von Willebrand factor, fibrinogen, prothrombin fragment 1 + 2, thrombin-antithrombin III complexes, tissue type plasminogen activator, tissue plasminogen activator inhibitor type 1, total cholesterol, HDL cholesterol, and triglycerides were measured before and after treatment. Of the patients, 31 completed the study.
We found no significant effect of heparin on markers of vascular wall and hemostatic function by any of the treatments.
Treatment with high- or low-dose heparin induced no modulation of markers of vascular wall or hemostatic function in IDDM patients with incipient diabetic nephropathy.
患有肾病的胰岛素依赖型糖尿病(IDDM)患者心血管疾病风险较高,可能是由血管壁功能异常介导的。我们研究了肝素是否能够调节早期肾病患者血管壁和止血功能的标志物。
35例早期肾病的IDDM患者在一项双盲试验中被随机分为接受安慰剂、普通肝素或低分子量肝素治疗。治疗采用1小时的传统静脉高剂量治疗,并按传统皮下低剂量方案治疗3个月。在治疗前后测量白蛋白的跨毛细血管逃逸率以及血管性血友病因子、纤维蛋白原、凝血酶原片段1 + 2、凝血酶 - 抗凝血酶III复合物、组织型纤溶酶原激活剂、组织型纤溶酶原激活剂抑制剂1型、总胆固醇、高密度脂蛋白胆固醇和甘油三酯的血浆水平。31例患者完成了该研究。
我们发现任何一种治疗方法对肝素的血管壁和止血功能标志物均无显著影响。
高剂量或低剂量肝素治疗均未对早期糖尿病肾病的IDDM患者的血管壁或止血功能标志物产生调节作用。